Aerie Pharma's combo eye
drug succeeds, shares soar
Send a link to a friend
[June 25, 2014]
(Reuters) - Drug developer
Aerie Pharmaceuticals Inc said its single-drop eye
treatment was shown to be superior to each of its two
components in a mid-stage trial, sending its shares up
by about 24 percent in premarket trading.
The drug, Roclatan, combines Aerie's other experimental glaucoma
drug Rhopressa with the approved latanoprost.
Patients treated with the drug experienced a significant reduction
in fluid pressure inside the eye, compared with those treated with
either latanoprost or Rhopressa.
Glaucoma is a condition in which increased eye pressure could damage
the optic nerve and lead to blindness, if left untreated.
Aerie Pharma said it would immediately start preparing for
Roclatan's late-stage trial.
It is also preparing to start a late-stage trial for Rhopressa early
in the third quarter.
The company's shares closed at $21.03 on the Nasdaq on Tuesday.
(Reporting By Amrutha Penumudi; Editing by Don Sebastian)
[to top of second column]
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.